LX 1033

Drug Profile

LX 1033

Alternative Names: LX-1033

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome(In volunteers) in USA (PO, Capsule)
  • 03 Dec 2013 Efficacy & adverse events data from a phase IIa trial in Irritable bowel syndrome (diarrhoea-predominant) released by Lexicon Pharmaceuticals
  • 30 Sep 2013 Lexicon Pharmaceuticals completes a phase II trial in Irritable bowel syndrome in USA (NCT01494233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top